CellFX System

DEVICE2 trials

Sponsors

Pulse Biosciences, Inc.

Conditions

BCCBCC - Basal Cell CarcinomaExcision MarginSebaceous HyperplasiaSkin AbnormalitiesSkin Lesion

Unknown Phase

Comparative Study Between CellFX and Electrodessication in Sebaceous Hyperplasia (SH) Lesions

CompletedNCT04539886

Pulse Biosciences, Inc.Sebaceous Hyperplasia, Skin Abnormalities, Skin Lesion

Start: 2020-09-28End: 2021-11-18Updated: 2024-04-25

CellFX Treat & Resect Low-Risk BCC Feasibility Study

CompletedNCT04918381

Pulse Biosciences, Inc.BCC, BCC - Basal Cell Carcinoma, Excision Margin

Start: 2021-06-02End: 2022-07-22Updated: 2023-01-11

Related Papers

Multicenter, prospective feasibility study of Nano-Pulse Stimulation™ technology for the treatment of both nodular and superficial low-risk basal cell carcinoma

Frontiers in Oncology2022-12-026 citations